Philogen S.p.A. is a Swiss-Italian integrated biotechnology company founded in 1996 by brothers Dario, Duccio, and Giovanni Neri. It specializes in developing innovative biopharmaceuticals, particularly armed antibodies targeting angiogenesis—the formation of new blood vessels implicated in severe conditions like cancer, rheumatoid arthritis, and age-related macular degeneration. As a pioneer in isolating, engineering, and clinically advancing human monoclonal antibodies that selectively target tumor neo-vasculature, Philogen has demonstrated efficacy in both animal models and cancer patients. The company currently advances four promising anti-cancer antibody derivatives and one for rheumatoid arthritis through clinical studies, supported by its proprietary technologies for rapid antibody isolation from large combinatorial libraries and its GMP production facility for clinical-grade therapeutic proteins. With around 50 employees and leadership from Professor Dario Neri, an ETH Zurich expert with extensive publications and awards, Philogen plays a key role in oncology and immunology, contributing cutting-edge antibody solutions to consortia like EURenOmics for diagnostics and personalized therapies in rare diseases. Headquartered in Sovicille, Italy, it underscores biotechnology's potential in addressing angiogenesis-related disorders.